…[Synthetic psilocybin] drug-backer Compass Pathways files for U.S. IPO
The London-based firm filed to raise US$100 million, a placeholder amount likely to change, according to a filing Friday [8/28/2020] with the U.S. Securities and Exchange Commission.
…has seen a renaissance in recent years in the scientific community. Scientists can’t exactly explain why psychedelics appear to help patients. Emerging brain-scanning technology suggests the substances can reboot a brain that shows signs of malfunction from what are essentially buggy pieces of neural code.
Original Article (BNN Bloomberg):
Magic mushroom drug-backer Compass Pathways files for U.S. IPO
Artwork Fair Use: EmmaWiki2020